Last updated on October 2006

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.


Brief description of study

The purpose of this study is to determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.

Detailed Study Description

- To determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias. - To determine the 2 and 3 year rate of locoregional disease control. - To evaluate the safety and toxicity of the combination of cetuximab and concomitant-boost accelerated radiotherapy followed by 12 weeks of complementary treatment with cetuximab. Both acute and chronic toxicity will be assessed. - To determine specific disease-free survival, event-free survival, disease-specific survival and overall survival - To determine acute and late toxicity - To determine EGFR, p53, Ki67, and evaluate its value as a prognostic factor.

Clinical Study Identifier: NCT00251381

Contact Investigators or Research Sites near you

Start Over

Alicia Lozano, MD

Institut Catala Oncologia: Hospital Duran y Reynals
Hospitalet de Llobregat, Spain
  Connect »

Palmira Foro, MD

H. del Mar / H. de la Esperanza
Barcelona, Spain
3.79miles
  Connect »

Manuel De Vega, MD

H. de la Santa Creu I Sant Pau
Barcelona, Spain
4.09miles
  Connect »

Antonio Arellano, MD

Hospital Germans Tries i Pujol
Badalona, Spain
4.74miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.